279 related articles for article (PubMed ID: 18056460)
41. Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin.
Li N; Liu Y; Pang H; Lee D; Zhou Y; Xiao Z
Med Sci Monit; 2019 Mar; 25():1590-1599. PubMed ID: 30821276
[TBL] [Abstract][Full Text] [Related]
42. Identification of the interleukin 4 receptor alpha gene as a direct target for p73.
Sasaki Y; Mita H; Toyota M; Ishida S; Morimoto I; Yamashita T; Tanaka T; Imai K; Nakamura Y; Tokino T
Cancer Res; 2003 Dec; 63(23):8145-52. PubMed ID: 14678968
[TBL] [Abstract][Full Text] [Related]
43. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
44. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
Canalli AA; Yang H; Jeha S; Hoshino K; Sanchez-Gonzalez B; Brandt M; Pierce S; Kantarjian H; Issa JP; Garcia-Manero G
Leuk Res; 2005 Aug; 29(8):881-5. PubMed ID: 15978938
[TBL] [Abstract][Full Text] [Related]
45. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Ibrahim N; He L; Leong CO; Xing D; Karlan BY; Swisher EM; Rueda BR; Orsulic S; Ellisen LW
Cancer Res; 2010 Sep; 70(18):7155-65. PubMed ID: 20807817
[TBL] [Abstract][Full Text] [Related]
46. Targeting p73--a potential approach in cancer treatment.
Slade N; Horvat A
Curr Pharm Des; 2011; 17(6):591-602. PubMed ID: 21391909
[TBL] [Abstract][Full Text] [Related]
47. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
48. Targeting p73 in cancer.
Maas AM; Bretz AC; Mack E; Stiewe T
Cancer Lett; 2013 May; 332(2):229-36. PubMed ID: 21903324
[TBL] [Abstract][Full Text] [Related]
49. Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.
Ge P; Yu X; Wang ZC; Lin J
Asian Pac J Cancer Prev; 2015; 16(9):4071-5. PubMed ID: 25987089
[TBL] [Abstract][Full Text] [Related]
50. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
[TBL] [Abstract][Full Text] [Related]
51. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling.
Zhang Y; Qu X; Jing W; Hu X; Yang X; Hou K; Teng Y; Zhang J; Liu Y
Anticancer Drugs; 2009 Mar; 20(3):208-14. PubMed ID: 19396019
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
[TBL] [Abstract][Full Text] [Related]
54. Alteration of p73 in pediatric de novo acute lymphoblastic leukemia.
Sahu GR; Das BR
Biochem Biophys Res Commun; 2005 Feb; 327(3):750-5. PubMed ID: 15649410
[TBL] [Abstract][Full Text] [Related]
55. Methylation-associated silencing of TU3A in human cancers.
Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
Int J Oncol; 2008 Oct; 33(4):893-9. PubMed ID: 18813805
[TBL] [Abstract][Full Text] [Related]
56. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
57. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
[TBL] [Abstract][Full Text] [Related]
58. Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas.
Ohta T; Watanabe T; Katayama Y; Yoshino A; Yachi K; Ogino A; Komine C; Fukushima T
Oncol Rep; 2006 Nov; 16(5):957-63. PubMed ID: 17016577
[TBL] [Abstract][Full Text] [Related]
59. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.
Di Agostino S; Cortese G; Monti O; Dell'Orso S; Sacchi A; Eisenstein M; Citro G; Strano S; Blandino G
Cell Cycle; 2008 Nov; 7(21):3440-7. PubMed ID: 18948736
[TBL] [Abstract][Full Text] [Related]
60. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
